Literature DB >> 10376893

Aerosolized albuterol sulfate used as a bronchodilator in horses with recurrent airway obstruction.

F J Derksen1, M A Olszewski, N E Robinson, C Berney, J E Hakala, C J Matson, D T Ruth.   

Abstract

OBJECTIVE: To determine the dose of aerosolized albuterol sulfate required to cause bronchodilation in horses with recurrent airway obstruction (RAO) and duration of this effect. ANIMALS: 19 horses with RAO (10 in experiment 1; 9 in experiment 2). PROCEDURE: Horses were moved from pasture to stables, and airway obstruction was induced. Pulmonary function was measured in 10 horses before and 5, 10, and 30 minutes after administration of vehicle or 120, 240, 360, or 720 microg of the drug. Nine horses received vehicle or 360 or 720 microg of albuterol, and pulmonary function was measured at baseline and 5 minutes and 1, 2, 3, 4, 5, 6, and 7 hours later. Horses were evaluated for adverse drug effects.
RESULTS: 360 microg of albuterol was required to cause significant bronchodilatation; 720 microg did not enhance bronchodilatation or increase duration of action. Depending on which pulmonary function parameter was evaluated, bronchodilatation achieved by use of albuterol lasted between 30 minutes and 1 hour. Because there was a significant vehicle effect, the combined effect of vehicle and drug lasted up to 3 hours. Adverse effects were not observed.
CONCLUSIONS: Aerosolized albuterol, 360 or 720 microg, is a safe and effective bronchodilator in horses with RAO. Onset of action is rapid (5 minutes), and effects last from 30 minutes to 3 hours. CLINICAL RELEVANCE: Aerosolized albuterol is useful for treatment of bronchospasm in horses with RAO.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10376893

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  9 in total

1.  Use of a novel one-nostril mask-spacer device to evaluate airway hyperresponsiveness (AHR) in horses after chronic administration of albuterol.

Authors:  Melissa R Mazan; Kara Lascola; Susan J Bruns; Andrew M Hoffman
Journal:  Can J Vet Res       Date:  2014-07       Impact factor: 1.310

2.  Pilot study investigating the ability of an herbal composite to alleviate clinical signs of respiratory dysfunction in horses with recurrent airway obstruction.

Authors:  Wendy Pearson; Armen Charch; Dyanne Brewer; Andrew F Clarke
Journal:  Can J Vet Res       Date:  2007-04       Impact factor: 1.310

Review 3.  Anesthesia of the geriatric equine.

Authors:  Reza Seddighi; Thomas J Doherty
Journal:  Vet Med (Auckl)       Date:  2012-08-03

4.  Receptor-mediated enhancement of beta adrenergic drug activity by ascorbate in vitro and in vivo.

Authors:  Patrick F Dillon; Robert Root-Bernstein; N Edward Robinson; William M Abraham; Catherine Berney
Journal:  PLoS One       Date:  2010-12-13       Impact factor: 3.240

5.  Cardiovascular changes after administration of aerosolized salbutamol in horses: five cases.

Authors:  Daniela Casoni; Claudia Spadavecchia; Chiara Adami
Journal:  Acta Vet Scand       Date:  2014-08-14       Impact factor: 1.695

Review 6.  Investigating the link between particulate exposure and airway inflammation in the horse.

Authors:  K M Ivester; L L Couëtil; N J Zimmerman
Journal:  J Vet Intern Med       Date:  2014-10-01       Impact factor: 3.333

7.  Fluticasone/salmeterol reduces remodelling and neutrophilic inflammation in severe equine asthma.

Authors:  Michela Bullone; Amandine Vargas; Yvonne Elce; James G Martin; Jean-Pierre Lavoie
Journal:  Sci Rep       Date:  2017-08-18       Impact factor: 4.379

8.  Efficacy of Inhaled Levalbuterol Compared to Albuterol in Horses with Recurrent Airway Obstruction.

Authors:  M G Arroyo; L L Couëtil; N Nogradi; M M Kamarudin; K M Ivester
Journal:  J Vet Intern Med       Date:  2016-06-09       Impact factor: 3.333

9.  The effect of single pretreatment with salbutamol on recovery of bronchoalveolar lavage fluid in horses with suspected or confirmed severe equine asthma.

Authors:  Mathilde S Varegg; Kine M Kløverød; Malin K Austnes; Natalia Siwinska; Malwina Slowikowska; Agnieszka Zak; Artur Niedzwiedz
Journal:  J Vet Intern Med       Date:  2019-02-01       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.